Our OvaSuite Portfolio
Planned for Clinical Management
- For adnexal masses initially evaluated as indeterminate or benign
- Negative Predictive Value of over 99%1
- Longitudinal monitoring feature to help providers track risk over time
Planned for Surgical Management
- For adnexal masses that are planned for surgery
- Ova1® has a greater than 96% sensitivity with clinical assessment2
- Biomarkers (including CA-125), menopausal status, and ultrasound for a personalized risk score
Ova1Plus is a reflex process: Ova1® is performed3 first. If an intermediate risk is detected, Overa® is automatically performed.
In the United States, there are approximately 9.1 surgeries per malignancy for adnexal masses, compared to just 2.3-5.9 in European centers. It's time to enhance our preoperative assessments.4
OvaSuite Portfolio Value
Superior Sensitivity vs. CA-125
(According to Peer-Reviewed Publications7)
-In peer-reviewed studies, Ova1 could outperform CA-125 alone in detecting malignancy risk across numerous histology types2.
-CMS NCD 190.28 “The CA-125 is specifically not covered for aiding in the differential diagnosis of patients with a pelvic mass as the sensitivity and specificity of the test is not sufficient”.
Surgical Reduction
-Could lower overall cost of care for women with adnexal masses.
-Up to 59% reduction in surgeries for premenopausal and asymptomatic women with OvaWatch5.
Health Equity
-Help improve the equity of adnexal mass care in non-white women with Ova17.
-Bridge the gap in ethnic disparities, particularly for African American patients With Ova1.
Ultrasound Discordance Solution
-Data shows that up to 50% of adnexal masses are considered indeterminate on imaging.
-Discordance in ultrasound interpretation is common.
-Utilize OvaSuite as an additional tool for enhanced risk assessment.
Appropriate Triage of Patients
-Triage more precisely.
-A peer-reviewed study shows the potential to avoid unnecessary oncologist referrals with Ova1.
-Provide peace of mind with OvaWatch for low-risk cases.
Supported by ACOG and SGO Professional Guidelines5,6
Case Study
Explore How Ova1Plus Transforms Ovarian Cancer Risk Assessment
Read real patient scenarios where Ova1Plus provided critical insights, helping to assess ovarian cancer risk and individualized treatment decisions.
Connect with Aspira Women's Health to help revolutionize adnexal mass management, individualize patient outcomes, and lead the way in gynecologic care innovation.
PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.
OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.
*In cases of an intermediate Ova1® result, the FDA-cleared Overa® reflex is performed to increase specificity